Vortioxetine vs placebo
Response · adults with Major Depressive Disorder
Vortioxetine may leads to higher response compared with placebo (low certainty).
1 finding from 1 review
- RR 1.35 [1.22, 1.49]14 studies · 6220 participantsLow
Findings
What do systematic reviews say?
35 questions · 35 findings · 2 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 22 · 62.9%Low 9 · 25.7%Moderate 4 · 11.4%High 0 · 0%
Vortioxetine vs SNRIs
Remission · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes remission compared with SNRIs (very low certainty).
1 finding from 1 review
- RR 0.89 [0.77, 1.03]8 studies · 3155 participantsVery low
Vortioxetine vs SNRIs
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
- no estimate extracted8 studies · 2807 participantsVery low
Vortioxetine vs SNRIs
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes drop‐out due to adverse events compared with SNRIs (very low certainty).
1 finding from 1 review
- RR 0.74 [0.51, 1.08]8 studies · 3159 participantsVery low
Vortioxetine vs SNRIs
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes drop‐out due to inefficacy compared with SNRIs (very low certainty).
1 finding from 1 review
- RR 1.52 [0.7, 3.3]8 studies · 3159 participantsVery low
Vortioxetine vs SNRIs
Tolerability · adults with Major Depressive Disorder
Vortioxetine may leads to lower tolerability compared with SNRIs (low certainty).
1 finding from 1 review
- RR 0.9 [0.86, 0.94]8 studies · 3134 participantsLow
Vortioxetine vs placebo
Total number of drop‐outs · adults with Major Depressive Disorder
Vortioxetine showed no clear difference in total number of drop‐outs compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.05 [0.93, 1.19]14 studies · 6220 participantsModerate
Vortioxetine vs placebo
Remission · adults with Major Depressive Disorder
Vortioxetine may leads to higher remission compared with placebo (low certainty).
1 finding from 1 review
- RR 1.33 [1.15, 1.53]14 studies · 6217 participantsLow
Vortioxetine vs placebo
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
- no estimate extracted14 studies · 5566 participantsVery low
Vortioxetine vs placebo
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
Vortioxetine probably leads to higher drop‐out due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.41 [1.09, 1.81]14 studies · 6220 participantsModerate
Vortioxetine vs placebo
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · adults with Major Depressive Disorder
Vortioxetine probably leads to lower drop‐out due to inefficacy compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.56 [0.34, 0.9]14 studies · 6220 participantsModerate
Vortioxetine vs placebo
Tolerability · adults with Major Depressive Disorder
Vortioxetine probably leads to higher tolerability compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.12 [1.07, 1.16]14 studies · 6182 participantsModerate
Vortioxetine vs SNRIs
Response · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes response compared with SNRIs (very low certainty).
1 finding from 1 review
- RR 0.91 [0.82, 1]8 studies · 3159 participantsVery low
Vortioxetine vs SNRIs
Total number of drop‐outs · adults with Major Depressive Disorder
It is very uncertain whether vortioxetine changes total number of drop‐outs compared with SNRIs (very low certainty).
1 finding from 1 review
- RR 0.89 [0.73, 1.08]8 studies · 3159 participantsVery low
Intervention not reported
mirtazapine:vortioxetine · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
vortioxetine:paroxetine · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
vortioxetine:sertraline · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
vortioxetine:venlafaxine · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
vilazodone:vortioxetine · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
vortioxetine:placebo · children and/or adolescents with depression
1 finding from 1 review
- New generation antidepressants for depression in children and adolescents: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low